BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34303630)

  • 1. Trends in Testosterone Therapy use in Prostate Cancer Survivors in the United States.
    Chen T; Li S; Eisenberg ML
    J Sex Med; 2021 Aug; 18(8):1346-1353. PubMed ID: 34303630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Testosterone Therapy in the Setting of Prostate Cancer.
    Rodriguez KM; Pastuszak AW; Khera M
    Curr Urol Rep; 2018 Jun; 19(8):67. PubMed ID: 29961247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
    Grabner M; Hepp Z; Raval A; Tian F; Khera M
    J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone Therapy After Prostate Cancer Treatment: A Review of Literature.
    Natale C; Carlos C; Hong J; Khera M; Baum N; Raheem OA
    Sex Med Rev; 2021 Jul; 9(3):393-405. PubMed ID: 33516741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy.
    Pastuszak AW; Pearlman AM; Lai WS; Godoy G; Sathyamoorthy K; Liu JS; Miles BJ; Lipshultz LI; Khera M
    J Urol; 2013 Aug; 190(2):639-44. PubMed ID: 23395803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy in the setting of prostate cancer treated with radiation.
    Pastuszak AW; Pearlman AM; Godoy G; Miles BJ; Lipshultz LI; Khera M
    Int J Impot Res; 2013 Jan; 25(1):24-8. PubMed ID: 22971614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Relationship Between PSA and Total Testosterone Levels in Men With Prostate Cancer.
    Flores JM; Bernie HL; Miranda E; Nascimento B; Schofield E; Benfante N; Carlsson S; Mulhall JP
    J Sex Med; 2022 Mar; 19(3):471-478. PubMed ID: 35135736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic response rates to testosterone therapy and the likelihood of completing 12 months of therapy in clinical practice.
    Rhoden EL; Morgentaler A
    J Sex Med; 2010 Jan; 7(1 Pt 1):277-83. PubMed ID: 20104673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between Hemoglobin A1c Levels and Inflatable Penile Prosthesis Infection: Analysis of US Insurance Claims Data.
    Chen T; Li S; Eisenberg ML
    J Sex Med; 2021 Jun; 18(6):1104-1109. PubMed ID: 34103256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality.
    Saad F; Caliber M; Doros G; Haider KS; Haider A
    Aging Male; 2020 Mar; 23(1):81-92. PubMed ID: 30782054
    [No Abstract]   [Full Text] [Related]  

  • 11. Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.
    Kaplan AL; Trinh QD; Sun M; Carter SC; Nguyen PL; Shih YT; Marks LS; Hu JC
    J Sex Med; 2014 Apr; 11(4):1063-1070. PubMed ID: 24443943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk.
    Khera M; Miner M; Jaffe J; Pastuszak AW
    J Sex Med; 2021 Jan; 18(1):83-98. PubMed ID: 33317996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Testosterone Treatment of Men with Unequivocal Hypogonadism Following Treatment of Organ-Confined Prostate Cancer.
    Jones RB; Snyder PJ
    Endocr Pract; 2023 Sep; 29(9):723-726. PubMed ID: 37236354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commentary: Who is a candidate for testosterone therapy? A synthesis of international expert opinions.
    Morgentaler A; Khera M; Maggi M; Zitzmann M
    J Sex Med; 2014 Jul; 11(7):1636-45. PubMed ID: 24797325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of testosterone therapy in men with prostate cancer.
    Morgentaler A; Caliber M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1065-1076. PubMed ID: 31495240
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-acting testosterone injections for treatment of testosterone deficiency after brachytherapy for prostate cancer.
    Balbontin FG; Moreno SA; Bley E; Chacon R; Silva A; Morgentaler A
    BJU Int; 2014 Jul; 114(1):125-30. PubMed ID: 25101359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testosterone therapy and prostate cancer.
    Pastuszak AW; Rodriguez KM; Nguyen TM; Khera M
    Transl Androl Urol; 2016 Dec; 5(6):909-920. PubMed ID: 28078223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.
    Walsh TJ; Shores MM; Krakauer CA; Forsberg CW; Fox AE; Moore KP; Korpak A; Heckbert SR; Zeliadt SB; Kinsey CE; Thompson ML; Smith NL; Matsumoto AM
    PLoS One; 2018; 13(6):e0199194. PubMed ID: 29933385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in Testosterone Therapy.
    Twitchell DK; Pastuszak AW; Khera M
    Sex Med Rev; 2021 Jan; 9(1):149-159. PubMed ID: 33309270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis and Treatment of Testosterone Deficiency: Updated Recommendations From the Lisbon 2018 International Consultation for Sexual Medicine.
    Morgentaler A; Traish A; Hackett G; Jones TH; Ramasamy R
    Sex Med Rev; 2019 Oct; 7(4):636-649. PubMed ID: 31351915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.